US Patent

US8058291 — Methods and compositions for the treatment of CNS-related conditions

Method of Use · Assigned to Adamas Pharmaceuticals Inc · Expires 2029-12-05 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel methods and compositions for treating and preventing CNS-related conditions, including Alzheimer's disease.

USPTO Abstract

The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1641`	—	donepezil-hydrochloride
`U-1641`	—	donepezil-hydrochloride
`U-1641`	—	donepezil-hydrochloride
`U-1641`	—	donepezil-hydrochloride

Patent Metadata

Patent number: US8058291
Jurisdiction: US
Classification: Method of Use
Expires: 2029-12-05
Drug substance claim: No
Drug product claim: No
Assignee: Adamas Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.